Details of the Chronic Kidney Disease Prognosis Consortium (CKD-PC) were described previously.3 (link)-6 (link) To be included in the consortium, a study had to have at least 1,000 participants (not applied to studies only enrolling CKD patients [CKD cohorts]6 (link)), information at baseline on eGFR and urine albumin levels, and a minimum of 50 events for any of the outcomes of interest. As recommended,1 (link),2 (link) we preferentially selected urine albumin-to-creatinine ratio (ACR) as the measure of albuminuria. However, we also accepted urine albumin excretion and urine protein-to-creatinine ratio (PCR) as well as a qualitative measurement using dipstick.1 (link) This analysis consists of data from 45 cohorts (25 general population cohorts, seven high-risk cohorts with participants selected for cardiovascular or kidney disease risk factors, and 13 CKD cohorts). Data transfer (from collaborating cohorts to the CKD-PC Data Coordinating Center) and analyses for the present study were conducted between March 2011 and March 2012. This study is based on secondary data analysis of pre-existing, de-identified/de-linked dataset, and was approved by the Institutional Review Board at the Johns Hopkins Bloomberg School of Public Health. Information about ethical review of individual studies is available in the publications of the constituent cohorts.21 (link),24 (link),27 (link)-69 (link)